Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Tortugas debuts with $106M and brain drugs from Hansoh, Eisai

 April 21, 2026

BioPharma Dive

Led by former Sage Therapeutics executives Jeff Jonas and Al Robichaud, the company is starting out with a portfolio of neurological medicines in clinical testing.

M&A / DealsNeuroscienceRead full story

Post navigation

Merck’s fast-ascending kidney cancer drug hits a setback →
← Health Canada approves Biocon’s two denosumab biosimilars

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com